Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 897-903

  Vukmirovic Popovic, Snezana ^a   Escott, Nicholas G ^b   Duivenvoorden, Wilhelmina C M ^a,c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d LAKEHEAD UNIVERSITY   (Canada)

Author keywords

Enzyme activity; Prostate cancer; Prostate specific antigen; Serum

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; FIBRONECTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TISSUE HOMOGENATE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRONECTINS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 54949155122     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000089     Document Type: Article

References (31)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, MD, 2004.
2. Jonsson M, Linse S, Frohm B, Lundwall A and Maim J: Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen. Biochem J 387: 447-453, 2005.
3. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899-1903, 1985.
4. Réhault S, Monget P, Mazerbourg S, et al: Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268: 2960-2968, 2001.
5. Webber MM, Waghray A and Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1: 1089-1094, 1995.
6. Ishii K, Otsuka T, Iguchi K, et al: Evidence that the prostate-specific antigen (PSA)/Zn(2+) axis may play a role in human prostate cancer cell invasion. Cancer Lett 207: 79-87, 2004.
7. Weir EG, Partin AW and Epstein JI: Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 163: 1739-1742, 2000.
8. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
9. Pampalakis G and Sotiropoulou G: Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 1776: 22-31,2007.
10. Magklara A, Scorilas A, Stephan C, et al: Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56: 527-532, 2000.
11. Qiu SD, Young CY, Bilhartz DL, et al: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144: 1550-1556, 1990.
12. Stege RH, Tribukait B, Carlstrom KA, Grande M and Pousette AH: Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 38: 183-188, 1999.
13. Stege R, Grande M, Carlstrom K, Tribukait B and Pousette A: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 6: 160-165, 2000.
14. Denmeade SR, Sokoll LJ, Chan DW, Khan SR and Isaacs JT: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48: 1-6, 2001.
15. Maim J, Hellman J, Hogg P and Lilja H: Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 45: 132-139, 2000.
16. Gleason DF: Histologic grading of prostate carcinoma: a perspective. Hum Pathol 23: 273-279, 1992.
17. Humphrey PA: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17: 292-306, 2004.
18. Horoszewicz JS, Leong SS, Kawinski E, et al: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
19. Sramkoski RM, Pretlow TG II, Giaconia JM, et al: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409, 1999.
20. Attardi BJ, Burgenson J, Hild SA and Reel JR: Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv 1 human prostate carcinoma cells. Mol Cell Endocrinol 222: 121-132, 2004.
21. Herrala A, Kurkela R, Vihinen M, Kalkkinen N and Vihko P: Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur J Biochem 255: 329-335, 1998.
22. Kumar A, Mikolajczyk SD, Hill TM, Millar LS and Saedi MS: Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 44: 248-254, 2000.
23. Webber MM and Waghray A: Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res 1: 755-761, 1995.
24. Corey E, Brown LG, Corey MJ, Buhler KR and Vessella RL: LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 35: 135-143, 1998.
25. Väisänen V, Lövgren J, Hellman J, Piironen T, Lilja H and Pettersson K: Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis 2: 91-97, 1999.
26. Kumar A, Mikolajczyk SD, Goel AS, Millar LS and Saedi MS: Expression of prostate-specific antigen by mammalian cells and its conversion to mature, active form by kallikrein 2. Cancer Res 57: 3111-3114, 1997.
27. Takayama TK, Fujikawa K and Davie EW: Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272: 21582-21588, 1997.
28. Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696-1701, 2006.
29. Saedi MS, Hill TM, Kuus-Reichel K, et al: The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 44: 2115-2119, 1998.
30. Dong Y, Kaushal A, Bui L, et al: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7: 2363-2371, 2001.
31. Deperthes D, Frenette G, Brillard-Bourdet M, et al: Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 17: 659-665, 1996.